Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 34, Issue 10, 2002, Pages 1396-1405

  Saveès, Marianne ^a   Raffi, Francçois ^b   Capeau, Jacqueline ^a   Rozenbaum, Willy ^e   Ragnaud, Jean Marie ^b   Perronne, Christian ^f   Basdevant, Arnaud ^c   Leport, Catherine ^d   Cheène, Genevieêve ^a   Salamon, R ^g   Brun Vezinet F ^g   Fleury, H ^g   Peytavin, G ^g   Moatti, J P ^g   Pierret, J ^g   Costagliola, D ^g   Dellamonica, P ^g   Katlama, C ^g   Meyer, L ^g   Morin, M ^g   Sicard, D ^g   Sobel, A ^g   Vincent Ballereau, F ^g   Dupon, M ^g   Le Moing, V ^g   Marchou, B ^g   May, T ^g   Morlat, P ^g   Waldner Combernoux, A ^g   Bard, J M ^g   Coussieu, C ^g   Gharakhanian, S ^g   Krempf, M ^g   Alfaro, C ^g   Barennes, C ^g   Cailleton, V ^g   Carrieri, M P ^g   Deveaud, C ^g   Droz, C ^g   Dupouy, G ^g   Duran, S ^g   Dutoit, S ^g   Ecobichon, J L ^g   Egouy, C ^g   Germain, C ^g   Jadand, C ^g   Journot, V ^g   Lassalle, R ^g   Latour, L ^g   Lawson Ayayi, S ^g   Lewden, C ^g   Masquelier, B ^g   Nouioua, W ^g   Palmer, G ^g   Pereira, E ^g   Roloff, S ^g   Ronde Ousteau V ^g   Sangue, A ^g   Souville, M ^g   Spire, B ^g   Surzyn, J ^g   Winum, R ^g   Chennebault, J M ^g   Faller, J P ^g   Estavoyer, J M ^g   Laurent, R ^g   Vuitton, D ^g   Beylot, J ^g   Lacut, J Y ^g   Le Bras, M ^g   Ragnaud, J M ^g   Granier, P ^g   Garre M ^g   Bazin, C ^g   Veyssier, P ^g   Devidas, A ^g   Perronne, C ^g   Lagarde, P ^g   Ceccaldi, J ^g   Peyramond, D ^g   Allard, C ^g   Reynes, J ^g   Canton, P ^g   Cassuto, J P ^g   Arsac, P ^g   Bricaire, F ^g   Caulin, C ^g   Frottier, J ^g   Herson, S ^g   Imbert, J C ^g   Malkin, J E ^g   Vachon, F ^g   Vilde J L ^g   Becq Giraudon, B ^g   Remy G ^g   Cartier, F ^g   Roue R ^g   more..

^a INSERM   (France)

^b Maladies Infectieuses et Tropicales   (France)

^c Serv de Med et Nutrition   (France)

^d PO B   (France)

^e Service de Maladies Infectieuses HÔpital Cochin AP HP   (France)

^f Service des Maladies Infectieuses et Tropicales   (France)

^g Hçpital Raymond Poincarè ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTHROPOMETRY; ARTICLE; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; METABOLIC DISORDER; PRIORITY JOURNAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; HIV INFECTIONS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; RITONAVIR; STAVUDINE;

EID: 0037093813     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/339866     Document Type: Article

References (47)

1. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
2. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
3. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
4. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
5. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
6. Clinical, biological and behavioral predictors of early immunological and virological response in HIV-infected patients initiating protease inhibitors
7. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
8. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
9. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
10. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adults treatment panel II)
11. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
12. Longitudinal data analysis using generalized linear models
13. A new look at the statistical model identification
14. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
15. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
16. Disorders of fat distribution in HIV infection
17. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
18. Frequency of lipodystrophy and factors associated with glucose-lipid abnormalities in a cohort of 650 patients treated by protease inhibitors
19. Insulin sensitivity and insulin clearance in human immunodeficiency virus infected men
20. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women
21. Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS
22. Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease inhibitors
23. Metabolic effects of indinavir in healthy HIV-seronegative men
24. Hypertriglyceridemia in the acquired immunodeficiency syndrome
25. Plasma lipids in HIV-infected patients: A prospective study in 95 patients
26. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens
27. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
28. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
29. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
30. Fat distribution and metabolic changes in patients with HIV infection
31. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease
32. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
33. Atherogen profile in HIV-1-infected patients with lipodystrophy syndrome
34. Lipodystrophies
35. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
36. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine cohort, France, 1999
37. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
38. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
39. Assessment of lipodystrophy in patients previously exposed to AZT, ddI or ddC, but naive for d4T and protease inhibitors (PI), and randomized between d4T/3TC/indinavir and AZT/3TC/indinavir (NOVAVIR trial)
40. Mitochondrial toxicitiy induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy related lipodystrophy
41. Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors
42. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study
43. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients
44. Antiretroviral therapy-associated hyperlipidaemia in HIV disease
45. Blood lipids of patients with chronic hepatitis: Differences related to viral etiology
46. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: A longitudinal study
47. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy